April 12, 2024
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-C3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
Select an appointment date and time from available spots listed below.